ROCO
4197
Market cap8mUSD
Oct 08, Last price
8.80TWD
1D
0.00%
1Q
0.80%
Jan 2017
-32.52%
IPO
-71.15%
Name
Visgeneer Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Visgeneer, Inc. engages in the provision of biotechnology service. It specializes in blood glucose testers, blood glucose test tablets, blood ketone testers, blood ketone test tablets, and and skin care products. The company was founded on November 15, 2005 and is headquartered in Hsinchu, Taiwan.
Key people
Weijie Chen
Deputy General Manager · since 2013
Jiazhen Zhang
Head of Finance & Accounting · since 2022
Zongwu Cai
Director · since 2017
Kengshuo Dai
Chairman of the Board, General Manager
Bin He
Director · since 2005
Benxian Zhang
Director · since 2021
Ching-Lung Lee
Independent Director · since 2021
Independent Director
Independent Director · since 2021
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||